Subtyping of male breast cancer by PAM50 and immunohistochemistry: a pilot study of a consecutive Danish cohort
| العنوان: | Subtyping of male breast cancer by PAM50 and immunohistochemistry: a pilot study of a consecutive Danish cohort |
|---|---|
| المؤلفون: | Marianne Djernes Lautrup, Anne Marie Bak Jylling, Lene Gaarsmand Christensen, Sören Möller, Maria Bibi Lyng |
| المصدر: | Christensen, L G, Lautrup, M D, Lyng, M B, Möller, S & Jylling, A M B 2020, ' Subtyping of male breast cancer by PAM50 and immunohistochemistry : a pilot study of a consecutive Danish cohort ', A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica, vol. 128, no. 9, pp. 523-530 . https://doi.org/10.1111/apm.13068Test |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Adult, Male, Risk, 0301 basic medicine, Microbiology (medical), Oncology, medicine.medical_specialty, Denmark, Pilot Projects, male breast cancer, Disease, Breast Neoplasms, Male, Pathology and Forensic Medicine, Cohort Studies, Surgical pathology, 03 medical and health sciences, 0302 clinical medicine, molecular pathology, Recurrence, Internal medicine, Biomarkers, Tumor, medicine, Humans, Immunology and Allergy, Aged, Aged, 80 and over, Molecular pathology, business.industry, Gene Expression Profiling, General Medicine, Middle Aged, medicine.disease, Immunohistochemistry, Subtyping, 030104 developmental biology, 030220 oncology & carcinogenesis, Male breast cancer, Cohort, histopathology, Histopathology, Genomic subtyping, business, surgical pathology |
| الوصف: | Male breast cancer (MBC) is a rare disease that is still to be fully understood. In female breast cancer, molecular subtyping by gene expression has proven its significance. In this study, we characterize a consecutive cohort of MBC patients surgically treated from 1997 to 2017, identified at our institution (N = 37), and report the association between molecular subtypes found by a surrogate panel of immunohistochemical (IHC) markers, and the PAM50 signature, as well as risk of recurrence score and overall survival for the different subtypes. PAM50 subtypes were determined using the nCounter FLEX system instrument and software. The distribution of molecular subtypes according to the PAM50 signature was as follows: 56% luminal B, 39% luminal A, and 5% basal-like. None of the tumors were HER2-enriched. Using IHC surrogate markers, we found 80% luminal B-like, 15% luminal A-like, and 5% basal-like. None were HER2-positive (non-luminal). We found a strong statistical association between subtypes found by PAM50 signature and the IHC surrogate markers (p |
| وصف الملف: | application/pdf |
| تدمد: | 1600-0463 0903-4641 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb7b71edb8d01d9fc31daada59d08c18Test https://doi.org/10.1111/apm.13068Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....eb7b71edb8d01d9fc31daada59d08c18 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16000463 09034641 |
|---|